&lt;p&gt;Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial&lt;/p&gt;

Furuhashi, Kazuki; Fujisawa, Tomoyuki; Dai, Huaping; Kamiya, Yousuke; Yasui, Hideki; Karayama, Masato; Suzuki, Yuzo; Hozumi, Hironao; Enomoto, Noriyuki; Inui, Naoki; Suda, Takafumi

doi:10.2147/jaa.s223093

Cited by 9 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The once-a-day combination of ICSLABA is also available that has an adherence advantage over twice-a-day combination. [ 70 71 72 73 74 75 76 ] Uncontrolled patients at step 4 may require additional therapy such as LAMA. Biologics are considered for uncontrolled patients with moderate-to-severe asthma based on phenotype.…”

Section: Impact Of Short-acting β-Agonists Overreliance On Asthma Gui...mentioning

confidence: 99%

Challenges and recommendations for the management of asthma in the Middle East and Africa

et al. 2022

View full text Add to dashboard Cite

Clinical presentation of asthma is variable, and its diagnosis can be a major challenge in routine health-care practice, especially in low-and-middle-income countries. The aim of asthma management is to achieve optimal asthma control and to reduce the risk of asthma exacerbations and mortality. In the Middle East and in Africa (MEA), several patient- and physician-related factors lead to misdiagnosis and suboptimal management of asthma. A panel of experts comprising of specialists as well as general health-care professionals met to identify challenges and provide recommendations for the management of asthma in MEA. The major challenges identified for diagnosis of asthma were lack of adequate knowledge about the disease, lack of specialized diagnostic facilities, limited access to spirometry, and social stigma associated with asthma. The prime challenges for management of asthma in MEA were identified as overreliance on short-acting β-agonists (SABAs), underprescription of inhaled corticosteroids (ICS), nonadherence to prescribed medications, and inadequate insurance coverage for its treatment. The experts endorsed adapting the Global Initiative for Asthma guidelines at country and regional levels for effective management of asthma and to alleviate the overuse of SABAs as reliever medications. Stringent control over SABA use, discouraging over-the-counter availability of SABA, and using as-needed low-dose ICS and formoterol as rescue medications in mild cases were suggested to reduce the overreliance on SABAs. Encouraging SABA alone-free clinical practice in both outpatient and emergency department settings is also imperative. We present the recommendations for the management of asthma along with proposed regional adaptations of international guidelines for MEA.

show abstract

Section: Impact Of Short-acting β-Agonists Overreliance On Asthma Gui...mentioning

confidence: 99%

Challenges and recommendations for the management of asthma in the Middle East and Africa

et al. 2022

View full text Add to dashboard Cite

show abstract

“…First, many preparations of inhaled therapy for chronic airways diseases require twice-daily dosing and higher-frequency dosing is associated with reduced adherence ( 10 ). A small study from 2019 comparing the effectiveness of a once-daily preparation of preventer medication to a standard twice-daily regimen noted a statistically significant reduction in forgetfulness and inconvenience as measured by a questionnaire ( 11 ). Second, asthma symptoms are known to vary with the time of day, the season, and even where the person lives and works, as seen in occupational and allergic asthma.…”

Section: Causes Of Poor Adherence To Inhaled Treatmentmentioning

confidence: 99%

A Clinical Perspective on the Role of Electronic Devices in Monitoring and Promoting Adherence in Airways Disease

Brennan

Mulvey

Greene

et al. 2021

Front. Med. Technol.

View full text Add to dashboard Cite

Poor adherence to treatment is a common reason why patients with chronic disease have worse outcomes than might be expected. Poor treatment adherence is of particular concern among people with airways disease because, apart from not taking treatment as prescribed, inhaled medication can also be administered incorrectly. Recently, a number of technological advances that accurately document when an inhaled treatment has been used and, in certain instances, how it was used have been developed. There is good evidence from a number of research groups that these devices, either by patient reminders or physician feedback, promote adherence to inhaled treatments. What is less certain is how, in a real-world setting, these devices change outcomes. In this perspective article, the role of electronic devices in quantifying treatment use and addressing poor treatment adherence and their potential role in clinical practice outside of clinical validation trials are described.

show abstract

“…FF/Vi DPI is the first once-daily ICS/uLABA recently commercialized in India for the treatment of COPD (FF/Vi: 100/25 µg) and Asthma (FF/Vi: 100/25 µg and 200/25 µg) [ 10 ]. Landmark studies for FF/Vi in COPD and Asthma found improved symptom control, improved adherence, and a lower need for rescue medication with FF/Vi than with conventional ICS/LABA, including budesonide/formoterol (BUD/FOR) [ 11 , 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts

Dhar

Talwar²,

James³

et al. 2022

ARM

View full text Add to dashboard Cite

Inhaled corticosteroid and ultra-long-acting beta-agonist (ICS/uLABA) combination is a recent advancement in the armamentarium against obstructive airways diseases (OADs). The combination of ICS/uLABA has several advantages, creating a favorable landscape for its utilization. Fluticasone furoate/vilanterol trifenatate (FF/Vi) is one such example of an ICS/uLABA. It offers several benefits from both drugs, such as a convenient once daily dosing schedule; high lipophilicity; high receptor affinity of fluticasone furoate along with high functional selectivity and a quick onset of action of vilanterol. However, the Global Initiative for Asthma (GINA) as well as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines do not clearly define the positioning of ICS/uLABA compared to conventional ICS/LABAs. There are a few areas of uncertainty especially around the appropriate reliever strategy with ICS/uLABA in Asthma. The current consensus was planned with a group of Indian pulmonology experts to provide more clarity on the potential use of FF/Vi in Asthma and COPD. The clinical statements highlighted in this consensus manuscript address crucial clinical questions revolving around the efficacy and safety of FF/Vi as compared to conventional ICS/LABAs and identify the ideal patient profile for its use. This consensus paper also sheds light upon the appropriate reliever to be used along with FF/Vi in Asthma and the utilization of FF/Vi-based triple therapy in OADs. Expert recommendations mentioned in this paper will serve as guidance to pulmonologists as well as consultant physicians who are involved in providing care to OAD patients and will help them weigh the various factors that need to be taken into account while prescribing ICS/uLABA combination.

show abstract

<p>Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial</p>

Cited by 9 publications

References 33 publications

Challenges and recommendations for the management of asthma in the Middle East and Africa

Challenges and recommendations for the management of asthma in the Middle East and Africa

A Clinical Perspective on the Role of Electronic Devices in Monitoring and Promoting Adherence in Airways Disease

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts

Contact Info

Product

Resources

About